Ahmet Soysal

Ahmet Soysal

Auto-generated profile, based on publicly available information

Ahmet Soysal

Clinic of Pediatrics, Memorial Ataşehir Hospital, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
EGErdem Gönüllü
Erdem Gönüllü
ASAhmet Soysal
Ahmet Soysal
SASerkan Atıcı
Serkan Atıcı
MEMesut Engin
Mesut Engin
OYOsman Yeşilbaş
Osman Yeşilbaş
NKNalan Karabayır
Nalan Karabayır
Developing an effective and safe vaccine against Covid-19 will facilitate return to normal. Due to hesitation toward the vaccine, it is crucial to explore the acceptability of the COVID-19 vaccine to the public and healthcare workers. In this cross-sectional survey, we invited 2251 pediatricians and 506 (22%) of them responded survey and 424 (84%) gave either nasopharyngeal swap or antibody assay for COVID-19 and 71 (14%) of them got diagnosis of COVID-19. If the effective and safe COVID-19 vaccine was launched on market, 420 (83%) of pediatrician accepted to get vaccine shot, 422 (83%) of them recommended vaccination to their family members, 380 (75%) of them accepted to vaccine their children and 445 (85%) of them offered vaccination to their pediatric patients. Among the participated pediatricians 304 (60%) of them thought COVID-19 vaccine should be mandatory. We found that there are high COVID-19 vaccine willingness rates for pediatricians for themselves, their own children, family members and their pediatric patients. We also found that being a pediatric subspecialist, believing in achieving an effective vaccine, willingness to participate in the phase 1–2 clinical vaccine trial, willingness to get an influenza shot this season, believing a vaccine and vaccine passport should be mandatory were significant factors in accepting the vaccine. It is important to share all information about COVID-19 vaccines, especially effectiveness and safety, with the public in a clear communication and transparency. The opposite will contribute to vaccine hesitancy and anti-vaccine movement.

23 July 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
ASAhmet Soysal
Ahmet Soysal
EGErdem Gönüllü
Erdem Gönüllü
IYİsmail Yıldız
İsmail Yıldız
MKMetin Karaböcüoğlu
Metin Karaböcüoğlu
The aim of the study was to investigate changes in the incidences of Varicella and Herpes Zoster (HZ) following introduction of single dose Varicella vaccine (VV) in Turkey. Changes in the incidences of varicella and HZ per 100,000 population were compared with pre (2011–2012) and post-VV period (2018–2019) throughout years between years 2011 and 2019 both for children and adults. In children ≤5 years of age, the annual incidences of varicella significantly decreased from 290 per 100000 children in 2011 to 24 per 100000 children in 2019 [p = .0001]. Also, for children ≤5 years the mean annual incidence of varicella decreased significantly [326/100000 ±51/100000 vs 23/100000 ± 1/100000; p = .014] between pre- and post-VV period. Moreover, the annual incidences of varicella significantly decreased from 43 per 100000 children in 2011 to 26 per 100000 children in 2019 in children age between 6 and 17 years. On the other hand, incidence of varicella in adult population (age >17 years) did not change significantly. Besides, the annual incidences of Herpes Zoster did not change significantly in children age stratas but significant increment observed in adult population. This increment was significant in adult age strata of 18–44 years, but non-significant in age strata of 45–64 years and >64 years. Thus, our study showed a significant reduction in the incidences of Varicella in children age stratas whereas significant increment in the incidence of HZ in adult population after the implementation of VV into the NIP of Turkey.

29 July 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
ASAhmet Soysal
Ahmet Soysal
EGErdem Gönüllü
Erdem Gönüllü
NKNalan Karabayır
Nalan Karabayır
SAServet Alan
Servet Alan
SASerkan Atıcı
Serkan Atıcı
MKMetin Karaböcüoğlu
Metin Karaböcüoğlu
The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.

24 September 2008 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
SDSerap Demir
Serap Demir
ASAhmet Soysal
Ahmet Soysal
MBM. Sinan Bakir
M. Sinan Bakir
MKMary E. Kaufmann
Mary E. Kaufmann
AYAysegul Yagci
Aysegul Yagci

30 July 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
ASAhmet Soysal
Ahmet Soysal
CBCanan Bilazer
Canan Bilazer
EGErdem Gönüllü
Erdem Gönüllü
EBEmine Barın
Emine Barın
MÇMahmut Çivilibal
Mahmut Çivilibal
Maternal vaccination with SARS-CoV-2 vaccines has not been well studied yet in terms of safety and efficacy for protecting the newborn by the placental passage of antibodies. We reported 34 years of old health care worker (HCW) without any known SARS-CoV-2 infection. She had the first dose of SARS-CoV-2 inactivated virus vaccine (CoronaVac, Sinovac Life Science Co, Ltd, Beijing, China) at a gestational age of 28 weeks. The second dose of vaccine was given four weeks later at a gestational age of 32 weeks. HCW did not report any vaccine-related adverse events after either the first or second dose of the vaccine. Three weeks after the second dose of the vaccine, her anti-receptor-binding domain (RBD) of SARS-CoV-2 spike protein antibody was 779 arbitrary units (AU) per ml. She gave a birth of 38 weeks three days gestation age of healthy, full-term girl with a birth weight of 2770 gr. The mother’s anti-RBD antibody was 734 AU/ml, the infant’s cord blood anti-RBD antibody level was 764 AU/ml, respectively, cord sera/maternal sera transfer ratio was 1,04. This infant is the first identified case of SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination with CoronaVac.

1 January 2017 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MŞMelis Şirinoğlu
Melis Şirinoğlu
ASAhmet Soysal
Ahmet Soysal
AKAyşe Karaaslan
Ayşe Karaaslan
EKEda Kepenekli Kadayifci
Eda Kepenekli Kadayifci
NYNilüfer Yalındağ-Öztürk
Nilüfer Yalındağ-Öztürk
MBM. Sinan Bakir
M. Sinan Bakir